

Paul E Sax

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1645456/publications.pdf>

Version: 2024-02-01

69
papers

5,560
citations

236612

25
h-index

102304

66
g-index

72
all docs

72
docs citations

72
times ranked

4895
citing authors

#	ARTICLE	IF	CITATIONS
1	Vigorous HIV-1-Specific CD4+ T Cell Responses Associated with Control of Viremia. <i>Science</i> , 1997, 278, 1447-1450.	6.0	1,780
2	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. <i>Lancet, The</i> , 2015, 385, 2606-2615.	6.3	521
3	Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. <i>Clinical Infectious Diseases</i> , 2020, 71, 1379-1389.	2.9	436
4	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. <i>Lancet, The</i> , 2012, 379, 2439-2448.	6.3	405
5	Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380â€“1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2017, 390, 2073-2082.	6.3	237
6	Should Resistance Testing Be Performed for Treatment-Naive HIV-Infected Patients? A Cost-Effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2005, 41, 1316-1323.	2.9	177
7	Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1964-e1972.	2.9	167
8	Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results. <i>Journal of Infectious Diseases</i> , 2011, 204, 1191-1201.	1.9	157
9	Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States. <i>PLoS ONE</i> , 2012, 7, e31591.	1.1	122
10	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virusâ€“1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 535-544.	2.9	122
11	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e211-e220.	2.1	108
12	Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2019, 6, e364-e372.	2.1	102
13	Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate. <i>Aids</i> , 2019, 33, 1455-1465.	1.0	99
14	Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. <i>Clinical Infectious Diseases</i> , 2022, 75, e450-e458.	2.9	84
15	Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 1276-1292.	6.3	82
16	Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. <i>Clinical Infectious Diseases</i> , 2018, 66, 1794-1797.	2.9	79
17	Generalizing Evidence from Randomized Trials Using Inverse Probability of Sampling Weights. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2018, 181, 1193-1209.	0.6	69
18	Challenges of â€œReturn to Workâ€“in an Ongoing Pandemic. <i>New England Journal of Medicine</i> , 2020, 383, 779-786.	13.9	65

#	ARTICLE	IF	CITATIONS
19	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. <i>Lancet HIV</i> , 2020, 7, e16-e26.	2.1	53
20	Tolerability and Safety of HIV Protease Inhibitors in Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 37, 1111-1124.	0.9	47
21	The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 60, 1102-1110.	2.9	41
22	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 33-42.	2.9	38
23	Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa415.	0.4	33
24	Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 39, 69-77.	0.9	32
25	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2017, 4, e486-e494.	2.1	31
26	Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. <i>Clinical Infectious Diseases</i> , 2020, 70, 1636-1642.	2.9	27
27	Atypical Skeletal Muscle Profiles in Human Immunodeficiency Virus-Infected Asymptomatic Middle-Aged Adults. <i>Clinical Infectious Diseases</i> , 2018, 66, 1918-1927.	2.9	26
28	Emergent Resistance to Dolutegravir Among INSTI-Na ⁺ ve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa202.	0.4	25
29	Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States. <i>Clinical Infectious Diseases</i> , 2020, 70, 1353-1363.	2.9	24
30	Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?. <i>Clinical Infectious Diseases</i> , 2017, 65, 1274-1281.	2.9	23
31	The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. <i>Journal of Infectious Diseases</i> , 2017, 216, 798-807.	1.9	22
32	Gender disparities in coronavirus disease 2019 clinical trial leadership. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1007-1010.	2.8	22
33	Beyond Efficacy: The Impact of Combination Antiretroviral Therapy on Quality of Life. <i>AIDS Patient Care and STDs</i> , 2005, 19, 563-576.	1.1	21
34	HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy?. <i>PLoS ONE</i> , 2014, 9, e113031.	1.1	21
35	Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 589-598.	0.9	20
36	Improving Influenza and Pneumococcal Vaccination Rates in Ambulatory Specialty Practices. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv119.	0.4	19

#	ARTICLE	IF	CITATIONS
37	Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA ≤ 500 copies/mL: week 48 outcomes from ACTG 5353. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1376-1380.	1.3	19
38	Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164. <i>HIV Clinical Trials</i> , 2010, 11, 248-259.	2.0	17
39	Antiretroviral Therapy and Efficacy After Virologic Failure on First-line Boosted Protease Inhibitor Regimens. <i>Clinical Infectious Diseases</i> , 2014, 59, 888-896.	2.9	15
40	Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 148-156.	0.9	14
41	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 268-280.	2.9	13
42	No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz056.	0.4	13
43	Antiretroviral therapy in older people with HIV. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 118-125.	1.5	13
44	Evaluation of Fever and Infections in Cardiac Surgery Patients. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2015, 19, 143-153.	0.4	12
45	Point-Counterpoint: Should Serum β -d-Glucan Testing Be Used for the Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia?. <i>Journal of Clinical Microbiology</i> , 2019, 58, .	1.8	11
46	Cystatin C-Based Renal Function Changes After Antiretroviral Initiation: A Substudy of a Randomized Trial. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu003.	0.4	10
47	Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10.	2.0	8
48	Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir. <i>PLoS ONE</i> , 2017, 12, e0181993.	1.1	8
49	Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 358-366.	0.9	7
50	Middle-Aged Men With HIV Have Diminished Accelerometry-Based Activity Profiles Despite Similar Lab-Measured Gait Speed: Pilot Study. <i>JMIR MHealth and UHealth</i> , 2019, 7, e11190.	1.8	7
51	Short and Long-Term Effects of Telaprevir on Kidney Function in Patients with Hepatitis C Virus Infection: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0124139.	1.1	6
52	Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1612-1614.	2.9	6
53	Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation. <i>Nature Communications</i> , 2020, 11, 2421.	5.8	6
54	Beginning Antiretroviral Therapy for Patients with HIV. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 421-438.	1.9	5

#	ARTICLE	IF	CITATIONS
55	Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx081.	0.4	5
56	Health Considerations for HIV-Infected International Travelers. <i>Current Infectious Disease Reports</i> , 2019, 21, 16.	1.3	4
57	Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1837-1842.	1.9	3
58	Initial therapy for HIV: can less be more?. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 535-537.	4.6	2
59	A Disturbing Decline. <i>New England Journal of Medicine</i> , 2019, 380, 2257-2262.	13.9	2
60	Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 254-255.	0.5	2
61	Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
62	Therapeutic options for treatment experienced patients: a focus on resistance testing and optimizing background therapy. <i>Aids Reader</i> , 2006, 16, 265-75, 277-8.	0.3	2
63	Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab648.	0.4	2
64	IgM Positivity for Both EBV and CMV: A Clinical Conundrum. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
65	A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination. <i>Open Forum Infectious Diseases</i> , 2017, 4, S426-S427.	0.4	1
66	Nearly Two Decades Later, Exciting Progress in HIV, But Challenges Remain. <i>Infectious Disease Clinics of North America</i> , 2019, 33, xiii-xiv.	1.9	1
67	Evaluation and management of early virological failure. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 409-416.	1.5	0
68	A Welcome to Open Forum Infectious Diseases (OFID). <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu001.	0.4	0
69	Antiretroviral Drug Recommendations for HIV Treatment and Prevention—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 889.	3.8	0